In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ProUroCare nets $2.7mm via public offering

Executive Summary

ProUroCare Medical (diagnostic devices for prostate disease) netted $2.7mm through the follow-on public offering of 3.05mm units at $1.00 apiece. Each unit is comprised of one common share and one warrant to buy one share exercisable at $1.30. The company will use part of the money to gain 510(k) clearance of its ProUroScan prostate imaging system.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies